Navigation Links
Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer

Clone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hu
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/23/2014)... , Sept. 23, 2014  Global Discovery Biosciences, a ... some of the biggest healthcare challenges, announces their collaboration ... accurate blood test for the early detection of lung ... of cancer death. Typically, the symptoms and subsequent diagnosis ... cancer, where the chance of a cure has already ...
(Date:9/23/2014)... 2014  Decision Resources Group finds that ... criteria and payer requirements in key pharmaceutical ... country, allow pharma to leverage similar payer ... access is extremely complex, with each country ... challenges—and a vast variety of local authorities ...
(Date:9/23/2014)... Calif. , Sept. 23, 2014 This test ... risk event. A "risk event" is defined by activities that can ... transfusions, tattoos, or use of any shared needles. ... HIV-2) in oral fluid. This HIV test works by looking ... Provides results in 20 minutes, enabling patients to learn ...
Breaking Medicine Technology:Global Discovery Biosciences Announces Collaboration with IPMD, Inc. to Develop Innovative Aptamer-Based Blood Test for the Early Detection of Lung Cancer 2Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 2Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 3Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 4WholeHealth Products announces the release of the FDA Cleared "HIV 1&2" Rapid Diagnostic Test for Professional and Retail 2
... Va., Aug. 30, 2011 Dilon expands its ... alliance with PenRad, rated #1 Mammography Information System ... innovation, high quality and customer loyalty are the ... provide leading-edge breast imaging tools, and an information ...
... announced the results of its Comprehensive Client Performance ... a 19 percent increase in their total revenue ... go-live. SuccessEHS believes this increase in revenue directly ... conjunction with the implementation of SuccessEHS software and ...
Cached Medicine Technology:Dilon Diagnostics® Partners With PenRad® 2Dilon Diagnostics® Partners With PenRad® 3SuccessEHS Solution Leads to 19 Percent Increase in Revenue 2SuccessEHS Solution Leads to 19 Percent Increase in Revenue 3
(Date:9/23/2014)... 2014 Mel Frank, also known as ... and harvesting marijuana. He is perhaps one of the ... he’ll be leading a special elective course on growing ... pm at Oaksterdam University in Oakland, California. ... nomenclature, harvesting and manicuring, and identifying preflowers and outdoor ...
(Date:9/23/2014)... September 23, 2014 Oaksterdam University has ... . In its first post, the University addresses the ... changing cannabis industry. , The cannabis industry is becoming ... is expecting an 18-month boost of more than $600 ... use pot sales. And, the new legal recreational marijuana ...
(Date:9/23/2014)... Mo. Infants, vocalizations throughout the first year ... and cooing to forming syllables and first words. ... amount of vocalizations may differ between hearing and ... that infant vocalizations are primarily motivated by infants, ... with profound hearing loss who received cochlear implants ...
(Date:9/23/2014)... 23, 2014 Florida Hospital Zephyrhills ... renovated Women’s Health Center on Wednesday, September 24. ... the specially designed center offers a new level ... County. The Women’s Health Center offers comprehensive women’s ... labor and delivery through The Baby Place®, and ...
(Date:9/23/2014)... 23, 2014 "The primary purpose of the ... an inventor from Sacramento, Ca.. "Call lights are often found ... hanging on the IV pole out of the patient's reach. ... call device whenever they need it, I created this caddy." ... the nurse call device within easy reach. The accessory ensures ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3
... cancer when it works with,the growth-promoting protein IL-3 and ... Tenn., Nov. 27 A gene called N-Myc,leads a ... is overexpressed,helping to trigger acute myeloid leukemia (AML) under ... conditions, according to,results of a mouse study done by ...
... CHAPEL HILL, N.C., Nov. 27 A story ... "colleague spam" -- the habit of,co-workers indiscriminately hitting ... New research by benchmarking leader Best Practices, LLC,uncovered ... spam" -- the,tendency of organizations to send redundant ...
... Failing Marks for Second Straight Year, WASHINGTON, Nov. ... Report Card on Lung Cancer. This,Report is an assessment ... state of Georgia. LCA-GA is a chapter of Lung ... patient support and,advocacy for people living with or at ...
... Nov. 27 The Aesthetic Extender,Symposium announced its inaugural ... which will be held in Miami Beach,Florida on October ... the first,and only event of its kind. Unlike other ... its mission statement a goal of adhering to,the policies ...
... Nov. 27 A new, free white ... on choosing the,right electronics manufacturing services (EMS) ... to download at, http://www.federalelec.com/medicalpaper ., Medical ... consistent quality and,conformance to product and regulatory ...
... E.S.T. - Positron emission tomography (PET) is a useful ... staging of lung cancer and improved treatment for patients, ... Journal of National Cancer Institute. , The ... of Cancer Care Ontarios Program in Evidence-Based Care led ...
Cached Medicine News:Health News:St. Jude Researchers Identify Key Genetic Trigger of Acute Myeloid Leukemia 2Health News:Using Efficient Communication to Boost Pharma Sales Force Productivity 2Health News:Lung Cancer Alliance-Georgia Issues Second Annual State-Specific Report Card on Lung Cancer 2Health News:Lung Cancer Alliance-Georgia Issues Second Annual State-Specific Report Card on Lung Cancer 3Health News:White Paper Details How to Choose the Right EMS Provider for Medical Products Outsourcing 2Health News:PET imaging significantly enhances standard imaging in lung cancer staging 2
The Properdin ELISA Kit is approved for in-vitro diagnostic use and measurement of properdin serum levels, relevant in cases of recurrent meningococcal infection and recurrent bacterial meningitis....
Inquire...
... can be used for a variety of vacuum needs ... or volatile fumes., Quiet running operation ... changes forever , Chemically Resistant ... solvents such as acids and organics. ...
High-intensity 300-watt xenon lamp, with continuously adjustable output from 0 to 100% manually or automatically by camera video output signal....
Medicine Products: